Advertisement

Topics

DBV Technologies to Attend Upcoming Investor Conferences

20:00 EDT 1 Jun 2015 | Globe Newswire

BAGNEUX, France, June 2, 2015 (GLOBE NEWSWIRE) -- DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that Susanna Mesa, Vice President Finance, Investor Relations & Strategy, will present and host investor meetings at the following upcoming investor conferences:

  • Jefferies 2015 Health Care Conference at the Grand Hyatt, New York, NY, on June 1-4, 2015.
  • Goldman Sachs 36th Annual Global Healthcare Conference at the Terranea Resort, Ranchos Palos Verdes, CA, on June 9-11.

A live audio webcast of the Jefferies' presentation will be available on the Investor Relations section of the Company's website, http://www.dbv-technologies.com/en/investor-relations. A replay of the presentation will also be available on DBV's website within 48 hours after the event.

About DBV Technologies

DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies - a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation and Breakthrough Therapy designation from the U.S. Food and Drug Administration.

DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com

DBV Technologies Contacts
Nathalie Donne Director, Corporate Communication & Business Development Tél. : +33(0)1 55 42 78 72 nathalie.donne@dbv-technologies.com Susanna Mesa VP Finance, US Investor Relations & Strategy
Tél. : +1 917-346-3447
susanna.mesa@dbv-technologies.com
DBV Technologies Media Contacts
Marion Janic
Rooney & Associates
Tél. : +1-212-223-4017
mjanic@rooneyco.com
 

DBV to present at upcoming Investor Conferences http://hugin.info/156437/R/1925519/690881.pdf

HUG#1925519

DBV Technologies logo

NEXT ARTICLE

More From BioPortfolio on "DBV Technologies to Attend Upcoming Investor Conferences"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...